Group 1 - WuXi AppTec, a leading player in the CXO sector, reported better-than-expected performance with double-digit growth in both revenue and net profit, maintaining a revenue guidance of RMB 41.5 billion to RMB 43 billion for 2025 [1] - In 2024, WuXi AppTec generated RMB 16.64 billion from the top 20 global pharmaceutical companies, highlighting its significant role in the global CXO market [1] - The Hong Kong innovation drug index saw a significant drop in P/E ratio from 64 times on February 21 to 27 times on April 28, indicating a strong value proposition for investors [1] Group 2 - The innovation drug ETF (159992) tracks an index that includes leading companies in the innovation drug industry, benefiting from trends such as AI-enabled drug development and the international expansion of domestic innovative drugs [2] - According to Insight database, there were 79 new drug license-out transactions in 2024, with 24 transactions completed in the first five months of 2025, totaling over USD 2 billion, showcasing the growing international recognition of Chinese innovative drugs [2] - Chinese pharmaceutical companies are demonstrating strong competitiveness in the global market through high-standard R&D, particularly in areas like antibodies and ADCs [2]